8-K: Aurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept (AUR200) in Autoimmune Diseases

Aurinia Pharmaceuticals Inc. announced positive Phase 1 single-ascending-dose study results for its dual BAFF/APRIL inhibitor, aritinercept (AUR200), demonstrating robust immunoglobulin reductions and good tolerability, supporting once-monthly dosing for autoimmune diseases.

Summary

• A Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), was conducted.
• The study involved 61 healthy subjects, investigating subcutaneous doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg, and 300 mg, along with placebo.
• Aritinercept was well tolerated across all tested dose levels, with no treatment-related Grade 3 adverse events, serious adverse events (SAEs), or discontinuations due to treatment-related adverse events.
• Common adverse events included injection site reactions (24% aritinercept, 13% placebo), headache (11% aritinercept, 7% placebo), upper respiratory tract infection (7% aritinercept, 0% placebo), and back pain (4% aritinercept, 0% placebo); all injection site reactions were Grade 1.
• Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins from baseline to Day 28: up to 48% for immunoglobulin A (IgA), 55% for immunoglobulin M (IgM), and 20% for immunoglobulin G (IgG).
• Pharmacodynamic effects observed are supportive of a once-monthly dosing regimen.
• Aurinia plans to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of 2025.

Sentiment

Score: 9

Explanation: The announcement of positive Phase 1 clinical trial results for aritinercept, demonstrating good tolerability and robust, long-lasting pharmacodynamic effects supportive of once-monthly dosing, is a significant positive milestone for Aurinia. The comparative data against other BAFF/APRIL inhibitors further strengthens the positive outlook for this pipeline asset.

Positives

• Aritinercept was well tolerated at all dose levels tested, indicating a favorable safety profile.
• No treatment-related Grade 3 adverse events or serious adverse events were reported.
• No discontinuations occurred due to treatment-related adverse events.
• Single doses of aritinercept resulted in robust and long-lasting reductions in immunoglobulins (IgA, IgM, IgG), demonstrating strong pharmacodynamic effects.
• The observed pharmacodynamic effects support a convenient once-monthly dosing schedule.
• Aritinercept exhibits high binding affinity for both BAFF and APRIL, and potently inhibits BAFFand APRIL-mediated B cell proliferation, outperforming or comparing favorably to competitor dual BAFF/APRIL inhibitors in preclinical and cross-trial comparisons.

Negatives

• Adverse events that occurred in more than one subject included injection site reactions (24% aritinercept vs. 13% placebo), headache (11% aritinercept vs. 7% placebo), upper respiratory tract infection (7% aritinercept vs. 0% placebo), and back pain (4% aritinercept vs. 0% placebo), though all injection site reactions were Grade 1.

Risks

• The development of aritinercept involves substantial risks and uncertainties that could cause actual outcomes to differ materially from current expectations.
• Additional risks and uncertainties are identified in Aurinia's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

Future Outlook

Aurinia plans to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of 2025, building on the positive Phase 1 results and the observed pharmacodynamic effects that support once-monthly dosing.

Management Comments

• "Dual inhibition of BAFF and APRIL to modulate B cells, including plasma cells, holds great promise in the treatment of a wide range of autoimmune immune diseases where these cells produce disease-causing autoantibodies."
• "Based on today's positive results, which indicate robust and long-lasting pharmacodynamic effects supportive of once-monthly dosing, we plan to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of this year."

Industry Context

Dual inhibition of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) is a significant therapeutic strategy in autoimmune diseases. This approach aims to modulate B cells, including plasma cells, which are responsible for producing disease-causing autoantibodies. Aurinia's focus on this mechanism aligns with broader industry efforts to develop targeted therapies for conditions with high unmet medical needs, complementing its existing FDA-approved therapy, LUPKYNIS (voclosporin), for lupus nephritis.

Comparison to Industry Standards

• Aritinercept demonstrated superior or comparable reductions in immunoglobulins compared to other dual BAFF/APRIL inhibitors in cross-trial comparisons of single-ascending-dose studies (no head-to-head clinical studies have been conducted).
• Mean IgA reductions from baseline to Day 28 for Aritinercept were up to 48%, which compares favorably to Povetacicept (-43%), Sibeprenlimab (-41%), Atacicept (-10%), and Telitacicept (7%).
• Mean IgM reductions from baseline to Day 28 for Aritinercept were up to 55%, which compares favorably to Povetacicept (-52%), Sibeprenlimab (-39%), Atacicept (-17%), and Telitacicept (6%).
• Mean IgG reductions from baseline to Day 28 for Aritinercept were up to 20%, which compares favorably to Povetacicept (-19%), Sibeprenlimab (-13%), and Telitacicept (7%). Atacicept showed no apparent reduction in serum IgG levels.
• Preclinical data indicates Aritinercept has higher binding affinity for both BAFF and APRIL and more potent inhibition of BAFFand APRIL-mediated B cell proliferation compared to Atacicept and Telitacicept.

Stakeholder Impact

• Shareholders: The positive Phase 1 results indicate promising pipeline development, potentially enhancing the company's long-term value and stock performance.
• Patients: The development of aritinercept offers potential for a new, effective, and conveniently dosed treatment option for a range of autoimmune diseases with high unmet medical needs.
• Employees: The successful clinical milestone validates the company's research and development efforts, potentially boosting morale and future opportunities within the organization.

Next Steps

• Initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of 2025.

Key Dates

Recommendation

Keywords

Aurinia Pharmaceuticals, AUPH, aritinercept, AUR200, Phase 1, clinical trial, autoimmune diseases, BAFF, APRIL, immunoglobulin, biopharmaceutical, drug development, clinical results, pharmacodynamics